Technological Advances Provide a Fillip to the European IV Therapy and Enteral Nutrition Devices Market, Notes Frost & Sullivan

LONDON, March 1, 2010 - The European intravenous (IV) therapy and enteral nutrition devices
market currently offers a highly dynamic and lucrative environment. Advances
in pharmacology and a wider range of blood products have substantially
increased the number of possible drug therapies, which can be used with IV
therapy devices. At the same time, developments in biotechnology are rapidly
expanding the range of available blood products.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (www.medicaldevices.frost.com),
European IV Therapy and Enteral Nutrition Devices Market, finds that the
market earned revenues of US$2423.0 million in 2008 and estimates this to
reach US$2981.2 million in 2012. The following segments are covered in the
research: catheters, infusion pumps, administration sets, feeding tubes and
feeding pumps.

"IV therapy devices companies are increasingly focusing on developing
computer-aided design for their products, resulting in improved and more
efficient coordination of procedures," notes Frost & Sullivan Senior Research
Analyst Janani Narasimhan. "Technological advances will not only make the
procedures safer but also smarter and more efficient for both IV therapy and
enteral nutrition devices."

IV therapy can be administered at home for patients who do not
necessarily need hospital care. European hospitals have recently enforced
strict regulations, which have resulted in the introduction of diagnostic
related groups (DRGs). This approach focuses solely on downsizing and
reducing the time spent by patients in hospitals.

This trend has significantly raised the value of homecare in Europe. In a
parallel development, it is now proven that IV therapy can be delivered
safely and effectively in patients' homes. Homecare provides greater
independence for patients along with cost-saving benefits, ensuring a win-win
situation.

A majority of the European IV therapy and enteral nutrition devices
market is held by a few tier-one and tier-two participants. This highly
concentrated market implies intense competition. Accordingly, market entry is
difficult. This acts as a major restraint as potential participants are being
driven out of the market. The end result is market stagnation and dynamism.

"The declining prices of IV therapy and enteral devices are chiefly due
to bulk purchases and tenders," adds Narasimhan. "Often manufacturers bundle
together products which results in the slashing of prices. It is not always
possible for smaller companies to reduce their prices and hence might lead to
further market consolidation."

The medical devices sector has been on a bull run for the past few years,
matching, if not frequently, exceeding growth expectations. No other sector
within healthcare has performed as consistently and successfully as medical
devices.

Medical device companies grew their aggregate top line at an annual rate
of eleven per cent. In the context of higher-end medical devices (which
contribute substantially towards the total market revenue), physician's
ability to perform certain procedures is often linked to the device itself.
Most of these devices are used in high-acuity setting and hence, cannot be
ignored.

"Companies that manufacture devices to treat life-threatening conditions
will continue to be immune to the recent economic tensions," concludes
Narasimhan. "Currently, the underlying demand for medical devices will lead
to a comparatively smooth business cycle and the market will, in all
probability, continue its strong lead."

European IV Therapy and Enteral Nutrition Devices Market is part of the
Medical Devices Growth Partnership Service programme, which also includes
research in the following markets: Western European Markets for Percutaneous
Coronary Intervention (PCI) Devices, Medical Devices Industry: Trends During
the Recession, Western European Markets for Wound Closure and, Medical Device
Company Profiles. All research included in subscriptions provide detailed
market opportunities and industry trends that have been evaluated following
extensive interviews with market participants.

If you are interested more information on the Frost & Sullivan study
European IV Therapy and Enteral Nutrition Devices Market, please send an
e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com,
with your full name, company name, title, telephone number, company e-mail
address, company website, city, state and country.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit www.frost.com.

           European IV Therapy and Enteral Nutrition Devices Market
                                   M456

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49(0)69-7703343
    E: katja.feick@frost.com
    www.frost.com
    Twitter: twitter.com/frost_sullivan

Katja Feick, Corporate Communications - Europe, Frost & Sullivan, +49(0)69-7703343, katja.feick at frost.com, Twitter: twitter.com/frost_sullivan